Answer: Monitoring postmarketing study commitments.
The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.
Answer: Monitoring postmarketing study commitments.
The FDA lacks an effective system for monitoring postmarketing study commitments. See the latest OIG Report, dated June 2006.